Want to join the conversation?
$PFE 2Q15 Q&A: Rubin of Goldman Sachs asked whether the company considers putting its Consumer business up for sale. Ian answered that Nexium OTC has been an incredible success and the company continues to invest in the Consumer business. At this moment, the Consumer business is a very valuable and growing asset for Pfizer, added Ian.
$BABA seems to be on a roll! But increasing its yearly sales outlook from 48% to 54% seems over-expectation from the company's part, doesn't it?
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?